Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASC302
- Development stage
- Preclinical
- Lead developer
- Asclepius Technology Group
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
ASC302 is an allogeneic natural killer (NK) cell therapy being developed by Ascle Therapeutics for the treatment of Parkinson's disease. It is part of the company's ASC3xx series, which focuses on neurological conditions using an allogeneic NK cell platform. The therapy utilizes NK cells derived from healthy donors, intended to provide an 'off-the-shelf' treatment option. While the specific molecular target has not been publicly disclosed, the mechanism of action is expected to involve NK-mediated immunomodulation and neuroprotective effects to address the neuroinflammation and underlying pathology associated with Parkinson's disease. It is currently in the preclinical stage of development.
Beyond the preview
Go deeper on ASC302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASC302.